ArticleOpen forum infectious diseases2026
Incidence of and Risk Factors for Tuberculosis Among Patients Treated for Hepatitis C: a Population-based Cohort Study.
Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: There is limited evidence on factors affecting tuberculosis (TB) disease development among patients treated for hepatitis C virus (HCV) infection. This study aimed to estimate the incidence of and risk factors for TB disease among patients treated within a national hepatitis C elimination program. Methods: We conducted a cohort study using nationwide electronic TB and HCV databases. The study population included adults who completed HCV treatment between April 2015 and December 2022. We calculated TB disease incidence rate (IR) per 100 000 person-years (PY) with 95% confidence intervals (CIs) overall and by subgroups: advanced liver fibrosis (fibroscan ≥ F3 or FIB-4 > 3.25), diabetes mellitus (DM) (fasting glucose level≥7 mmol/l or self-reported diabetes), and low body mass index (BMI < 18.5). Poisson regression was used to estimate adjusted incidence rate ratio (aIRR) and 95% CIs. Results: Among 75 693 individuals who completed treatment for hepatitis C, 544 new TB cases were identified over a median follow-up period of 69 months, corresponding to an IR of 136 per 100 000 PY (95% CI: 125, 148). Individuals with DM had a 53% higher incidence of TB (aIRR = 1.53; 95% CI: 1.09, 2.07) compared to those without. Underweight individuals (BMI < 18.5) had a higher incidence of TB compared with those of normal weight (aIRR 2.8; 95% CI: 1.67, 4.41). Advanced liver fibrosis was not significantly associated with TB disease (aIRR = .95, 95% CI: 0.72, 1.24). Conclusions: Individuals successfully treated for hepatitis C experienced high incidence of TB disease. Our findings suggest hepatitis C care programs may reduce TB risk by including DM screening and nutritional assessments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.